Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-207 pemigatinib in previously treated FGFR-altered solid tumors
2018-004768-69Phase 2Completed
- Sponsor
- Incyte
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pemigatinib in Non-hematologic malignancy (2 cohorts), sponsored by Incyte. Primary endpoint: Objective response rate in Cohort A. Started May 2019; status: completed.
02
Drugs
pemigatinib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2018-004768-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004768-69.